Anupam Rasayan India Limited — Investor Meet, 30-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Anupam Rasayan reported strong FY26 financials: Revenue up 65% YoY to INR 2,384 Cr, EBITDA at INR 543 Cr (23% margin), PAT INR 222 Cr (9% margin). Operating cash flow hit INR 334 Cr. Management highlighted strategic diversification, reducing agrochemicals reliance to 55%, while growing pharma (20%) and performance materials (18%). Key acquisitions (Tanfac, Jayhawk, Bliss GVS Pharma) build an integrated global platform, aiming to unlock significant synergies and leverage underutilized assets. Capex programs are complete, with no major capex planned. Management expressed confidence in a 20-30% organic growth trajectory, supplemented by these strategic moves. The company projects over INR 4,000 Cr pro forma revenue.